AbbVie Operating Margin 2010-2023 | ABBV

Current and historical operating margin for AbbVie (ABBV) over the last 10 years. The current operating profit margin for AbbVie as of December 31, 2023 is 36.40%.
AbbVie Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2023-12-31 $54.32B $12.76B 23.49%
2023-09-30 $55.14B $15.06B 27.32%
2023-06-30 $56.02B $17.39B 31.03%
2023-03-31 $56.74B $16.17B 28.49%
2022-12-31 $58.05B $18.12B 31.21%
2022-09-30 $57.82B $17.69B 30.59%
2022-06-30 $57.35B $17.39B 30.33%
2022-03-31 $56.73B $18.54B 32.68%
2021-12-31 $56.20B $17.92B 31.89%
2021-09-30 $55.17B $16.60B 30.09%
2021-06-30 $53.73B $15.55B 28.95%
2021-03-31 $50.20B $11.86B 23.63%
2020-12-31 $45.80B $11.36B 24.81%
2020-09-30 $40.65B $11.57B 28.45%
2020-06-30 $36.23B $10.93B 30.17%
2020-03-31 $34.06B $13.58B 39.86%
2019-12-31 $33.27B $12.98B 39.03%
2019-09-30 $32.87B $6.59B 20.04%
2019-06-30 $32.62B $7.13B 21.85%
2019-03-31 $32.65B $6.49B 19.88%
2018-12-31 $32.75B $6.38B 19.49%
2018-09-30 $32.19B $10.61B 32.95%
2018-06-30 $30.95B $10.14B 32.77%
2018-03-31 $29.61B $10.04B 33.91%
2017-12-31 $28.22B $9.55B 33.83%
2017-09-30 $27.27B $10.08B 36.95%
2017-06-30 $26.71B $9.74B 36.48%
2017-03-31 $26.22B $9.47B 36.12%
2016-12-31 $25.64B $9.34B 36.43%
2016-09-30 $25.24B $9.14B 36.21%
2016-06-30 $24.75B $8.66B 35.00%
2016-03-31 $23.78B $8.13B 34.18%
2015-12-31 $22.86B $7.54B 32.97%
2015-09-30 $21.91B $5.01B 22.86%
2015-06-30 $20.99B $4.08B 19.46%
2015-03-31 $20.44B $3.75B 18.33%
2014-12-31 $19.96B $3.41B 17.09%
2014-09-30 $19.62B $5.36B 27.33%
2014-06-30 $19.26B $5.77B 29.97%
2014-03-31 $19.02B $5.71B 30.01%
2013-12-31 $18.79B $5.66B 30.14%
2013-09-30 $18.89B $5.95B 31.51%
2013-06-30 $18.74B $6.18B 32.96%
2013-03-31 $18.54B $6.14B 33.15%
2012-12-31 $18.38B $5.82B 31.65%
2012-09-30 $18.04B $-1.89B -10.48%
2012-06-30 $17.94B $0.92B 5.14%
2012-03-31 $17.72B $3.77B 21.30%
2011-12-31 $17.44B $3.62B 20.75%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.653B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67